Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling. You can also look for studies that offer remote participation from home!
Getting a driver’s license is something that teens-including those with Congenital Heart Disease (CHD)-may look forward to. Although we know a lot about teenage driving and the programs in place to support learning this skill, we know very little about the early driving experiences of teenagers with CHD.
We are looking for teens with CHD who are 15 to 19 years old and have a learner’s permit or valid driver’s license, or interest in obtaining a learner’s permit or driver’s license and their parent/legal guardian. The study will be conducted remotely.
The electronic health record will be reviewed by a member of the study team, and teens and parents/legal guardians will be asked to complete demographic and health assessment surveys. Each teen and parent will participate in separate 45-minute video interviews to talk about what things support driving with a CHD and things that might make it harder to do. The video interview will take place on a video conferencing site using a computer or smartphone.
The total study participation time for each person (teen and parent/legal guardian) is 60 minutes. All teens and parents/legal guardians who participate will be compensated for their effort.
This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of the study drug are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing sarcoma.
This is a study to measure the effectiveness of the medication voclosporin compared to placebo in adolescent patients with active lupus nephritis. Volcosporin is an outpatient, oral medication.
This two-phase study is being conducted to determine the reasons why some children with newly diagnosed Crohn's disease heal their bowel inflammation after one type of therapy and why others do not. To do this, the study team will ask to collect blood, stool and biopsy (tissue) samples from participants newly diagnosed with Crohn's disease to measure their inflammation markers and evaluate their genes (DNA). To determine how much a participant's bowels have healed, we will also compare colonoscopy and MRE results that occur as part of the participant's standard clinical care.
This research is studying a vaccine against Mpox (formerly known as monkeypox) that is FDA approved for adults but not yet approved for children. The goal of the study is to determine if the vaccine protects children just as well as it protects adults. The study is also looking at the safety of the vaccine. This study is open to healthy adolescents, ages 12-17. In addition, adolescents with certain immunodeficiency diseases or other conditions, that are well controlled, are eligible to participate.
The purpose of this research study is to understand
the
impact of transplant on the quality of life of the entire family including
sibling donors, other siblings and parents.
The purpose of this research study is to examine relationships between brain and behavior development in toddlers with and without autism who have older siblings.
You may qualify for our study if you or your child's healthcare provider has concerns regarding your toddler's development (communication, motor, behavior, or social concerns or developmental concerns). Toddlers must have older biological sibling(s) without autism.
The study will enroll male and female patients between 2 years to 25 years of age with sickle cell disease or beta thalassemia major, who do not have a matched related donor, and their doctor feels their condition should be treated with hematopoietic stem cell transplantation (HSCT).
· -For Sickle Cell Disease, individuals must have significant disease. We would consider you for transplant if you have had severe neurologic symptoms including stroke, frequent vaso-occlusive events (examples include pain episodes requiring pain management or acute chest syndrome), or administration of regular and frequent red blood cell transfusions to prevent disease complications.
· -For Beta-Thalassemia Major, you would be considered a
candidate for transplant if you have genetic test confirming Beta Thalassemia
and have required 8 or more transfusions per year in the past two years.
The purpose of this research study is to test a new method of cell processing for stem cell transplants with a closely matched unrelated donor. The new method is called alpha/beta T cell and B cell depletion using a device called CliniMACs. We want to see if this method can reduce some of the complications of the transplant and decrease the time it takes for the new stem cells to establish a new immune system. The use of the CliniMACs device for alpha/beta T and B cell depletion is experimental and is considered research.
The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as UCART22 (“study drug”). UCART22 cells are special types of cells called T-cells that have been collected from a donor and then are genetically modified (changed). T-cells are related to your immune system, which helps to fight infection. These T-cells will be changed in a way that will allow the cells to identify and kill your tumor cells.
Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) whose disease has come back or have not responded to treatment may be eligible for this study.
Are you interested learning about opportunities to participate in research? Sign up to receive information about new research studies at CHOP. It’s a great way to support the work of the Research Institute.